CN1449783A - Traditional Chinese medicine formule for treating hyperlipemia - Google Patents
Traditional Chinese medicine formule for treating hyperlipemia Download PDFInfo
- Publication number
- CN1449783A CN1449783A CN 03109063 CN03109063A CN1449783A CN 1449783 A CN1449783 A CN 1449783A CN 03109063 CN03109063 CN 03109063 CN 03109063 A CN03109063 A CN 03109063A CN 1449783 A CN1449783 A CN 1449783A
- Authority
- CN
- China
- Prior art keywords
- prescription
- group
- radix
- effect
- hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 24
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 23
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- 210000004351 coronary vessel Anatomy 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 20
- 241000700159 Rattus Species 0.000 description 15
- 206010002383 Angina Pectoris Diseases 0.000 description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 208000029078 coronary artery disease Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000000465 moulding Methods 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 7
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 7
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 6
- 229960001214 clofibrate Drugs 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- -1 acyl coenzyme A Chemical compound 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960002545 methylthiouracil Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010058144 Postinfarction angina Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001961 meglutol Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine prescription for curing hyperlipemia is made from 6 Chinese medicinal materials of rhubarb, fetid cassia seed, salvia root, tangerine peel, ginseng and poria, its therapeutic effect is reliable, and its toxic side effect is less, it is applicable to patients with the diseases of angiocardiopathy and cerebrovascular disease of hypercholesterolemia and hypertriglyceridemia, and has the actions of expanding coronary artery and protecting myocardial ischemia.
Description
Affiliated technical field
The present invention relates to a kind of prescription for the treatment of hyperlipidemia, a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
Cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction, apoplexy are common clinically class diseases, and M ﹠ M is first of all kinds of diseases, serious harm human life and health.Therefore and hyperlipidemia is the inducement of atherosclerosis, coronary heart disease, apoplexy, myocardial infarction, and it is very important to preventing and treating above-mentioned disease to reduce plasma cholesterol, triglyceride, low density lipoprotein, LDL.Myocardial infarction is too high also relevant with arteria coronaria blood vessel and microcirculatory vascular tension force thereof, and antiotasis too high with blood plasma in triglyceride, cholesterol level too high also relevant, think above-mentioned at present and cross strong close relation, so it is very important with cholesterol and triglyceride in anticalcium and the reduction blood plasma to prevent and treat myocardial infarction with calcium channel is active.Clinical proof reduces plasma cholesterol and triglyceride concentration, can reduce the danger of myocardial infarction.
At present the lipid lowerers of using clinically as: meglutol list acyl coenzyme A (HMG-CoA) is though Western medicine such as reductase inhibitor, propylene glycol alginate sodium sulfate, clofibrate, nicotinic acid, colestyramine have curative effect preferably, but all have stronger toxic and side effects, the prolonged application that is unsuitable for patient is with the control cardiovascular and cerebrovascular disease.
Though the Chinese patent medicine of some treatment hyperlipidemias is also arranged, or because it costs an arm and a leg, the patient is difficult to bear; Or because its effect is not fairly obvious, the patient still has to depend on some Western medicine.
Summary of the invention
The objective of the invention is to overcome above-mentioned weak point, provide a kind of and fill a prescription rationally, reduce serum levels of triglyceride and cholesterol, and the effective Chinese medicine preparation of the high-efficiency low-toxicity of control cardiovascular and cerebrovascular disease.
In order to achieve the above object, the technical solution used in the present invention is: Radix Et Rhizoma Rhei 30-50%; Semen Cassiae 30-40%; Radix Salviae Miltiorrhizae 10-20%; Pericarpium Citri Reticulatae 5-10%; Radix Ginseng 2-5%; Poria 2-5%
The advantage that the present invention has is: this invention prescription rationally; medicine source abundance; with low cost; determined curative effect; toxic and side effects is little, be applicable to have hypercholesterolemia, the cardiovascular and cerebrovascular disease patient of hypertriglyceridemia, and coronary artery dilator and ischemic myocardial protection effect are arranged; especially coronary heart disease, the patient with angina pectoris to having hyperlipidemia, curative effect is better.
The specific embodiment
Below embodiments of the invention are described in further detail:
Embodiment 1:
Radix Et Rhizoma Rhei 240g, Semen Cassiae 210g, Radix Salviae Miltiorrhizae 90g, Pericarpium Citri Reticulatae 30g, Radix Ginseng 15g, Poria 15g
Embodiment 2:
Radix Et Rhizoma Rhei 180g, Semen Cassiae 180g, Radix Salviae Miltiorrhizae 120g, Pericarpium Citri Reticulatae 60g, Radix Ginseng 30g, Poria 30g
Embodiment 3:
Radix Et Rhizoma Rhei 300g, Semen Cassiae 180g, Radix Salviae Miltiorrhizae 60g, Pericarpium Citri Reticulatae 30g, Radix Ginseng 15g, Poria 15g
Embodiment 4:
Radix Et Rhizoma Rhei 240g, Semen Cassiae 180g, Radix Salviae Miltiorrhizae 60g, Pericarpium Citri Reticulatae 60g, Radix Ginseng 30g, Poria 30g
Embodiment 5:
Radix Et Rhizoma Rhei 180g, Semen Cassiae 210g, Radix Salviae Miltiorrhizae 120g, Pericarpium Citri Reticulatae 60g, Radix Ginseng 12g, Poria 18g
Embodiment 6:
Radix Et Rhizoma Rhei 210g, Semen Cassiae 180g, Radix Salviae Miltiorrhizae 120g, Pericarpium Citri Reticulatae 60g, Radix Ginseng 12g, Poria 18g
Solution of the present invention be according to theory of integrated Chinese and western medicine and clinical experiment and repeatedly prescription screening obtain having the spleen invigorating invigorating middle warmer, rush down turbid removing blood stasis, eliminating damp-heat, blood circulation promoting and blood stasis dispelling, the body resistance strengthening and constitution consolidating, the homologous natural edible-plant medicine of medicated diet.And in conjunction with the dialectical theoretical foundation of Chinese and western medicine of the Chinese herbal medicine of respectively distinguishing the flavor of in the prescription, the spleen invigorating invigorating middle warmer is to effect a permanent cure, rush down turbid relieving constipation to take stopgap measures, specimen is asked altogether, and then temper must be good for, turbid damp must go, stagnant down, all cards reach the effect that reduces plasma cholesterol and triglyceride from removing, and have coronary artery dilator, anticalcium, anticoagulant and thrombotic effect, thereby cardiovascular and cerebrovascular diseases such as performance prevention coronary heart disease, myocardial infarction, apoplexy take place and the effect of development.
Theory of Chinese medical science thinks that hyperlipidemia is plain body deficiency of spleen-QI, and the fortuneization malfunction easily changes turbid damp and checks meridians; Or feelings will shape rings and to make depression of liver-QI, excessive rising of liver-YANG, and the prosperous gram of wood is native, the impaired fortune imbalance of spleen and stomach function, the turbid damp intrinsic heat that reduces phlegm; Or have a liking for the food delicious food, pure surging cheese also makes " wet and be subjected to from interior ", gives birth to wet-living expectorant-heat-transformation.So disease relates generally to liver, spleen two is dirty, hold under the arm assorted eventually to turbid damp and expectorant stasis of blood void for sick.Its treatment should be followed on the basis that focuses on " removing the relative excess " and hold concurrently with the spleen invigorating tonify deficiency.
The present invention adopts Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, coronary artery dilator, anticalcium, anticoagulant to reach the purpose of prevention thrombosis; Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Semen Cassiae cholesterol reducing and triglyceride; Radix Ginseng, Pericarpium Citri Reticulatae, Poria improve liver, renal function and adjusting immunization, make lipid metabolism normal.Comprehensive all medicines originally can cholesterol reducing and the content of triglyceride, with the treatment hyperlipidemia, simultaneously certain coronary dilating is arranged again, improves blood supply of cardiac muscle and suppresses thrombotic effect, has the better prevention meaning to preventing and treating coronary heart disease, myocardial infarction and hyperlipidemia.
Test example 1: prescription of the present invention is to the effect for reducing fat of hyperlipemia rat
72 of male rats are divided into 6 groups at random, and 12 every group begin experiment after animal housing's habituation is raised 7 days.Matched group gives normal diet, and moulding group and each reagent group give special moulding feedstuff (30% Semen Maydis powder, 20% lining, 38% roughage, 2% cholesterol, 0.2% methylthiouracil, the big oil of 10% pig), every Mus feeding every day amount 10 grams.Each organizes equal gastric infusion, the moulding group gives normal saline, this each dosage group of filling a prescription is respectively 0.1g/kg every day, 0.2g/kg, 0.4g/kg, clofibrate 70mg/kg group, successive administration was got blood after 10 days, surveyed and respectively organized rat blood serum triglyceride (TG), serum total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein, LDL (LDL) content.
The results are shown in Table 1: this prescription obviously reduces TC, TG and the LDL in the hyperlipemia rat serum, and HDL is not had obvious influence, falls the hyperlipidemia effect and is same as clofibrate.
Table 1 prescription of the present invention is to the effect for reducing fat of hyperlipemia rat
The solid serum glycerol three high density lipoprotein level low-density lipoproteins of the total gallbladder of dosage serum
Group
(g/kg) alcohol (mg/dl) fat (mmol/L white (mmol/L) white (mmol/L)
Matched group 1.72 ± 0.26 0.40 ± 0.10 1.38 ± 0.27 0.66 ± 0.16
Moulding group normal saline 2.93 ± 0.36## 0.80 ± 0.29## 1.54 ± 0.21 1.56 ± 0.23##
This fills a prescription 0.1 2.57 ± 0.51 0.76 ± 0.2 1.53 ± 0.20 1.45 ± 0.25
This 0.2 2.26 ± 0.29**, 0.58 ± 0.17* 1.62 ± 0.25 0.99 ± 0.29** that fills a prescription
This 0.4 2.03 ± 0.34**, 0.53 ± 0.15** 1.52 ± 0.17 0.84 ± 0.26** that fills a prescription
Clofibrate 0.07 2.22 ± 0.43** 0.58 ± 0.19* 1.59 ± 0.28 0.91 ± 0.21**
X ± SD, n=12, * p＜0.05, * * p＜0.01 and moulding group compare ##p＜0.01 and matched group compares
Test example 2: prescription of the present invention is to the effect for reducing fat of hyperlipidemia Carnis Coturnicis japonicae
72 of male Carnis Coturnicis japonicaes, the habitual raising after 7 days is divided into 6 groups, 12 every group at random.Matched group gives normal diet, and moulding group and each reagent group give moulding feedstuff (88.9% normal diet, 1% cholesterol, 0.1% methylthiouracil, the big oil of 10% pig), ad lib, sub-cage rearing.The moulding group gives normal saline, this each dosage group of filling a prescription is respectively 0.1g/kg every day, 0.2g/kg, 0.4g/kg, clofibrate 70mg/kg group, behind the successive administration 10 days, carotid artery cuts gets blood, surveys and respectively organizes Carnis Coturnicis japonicae serum levels of triglyceride (TG), serum total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein, LDL (LDL) content.
The results are shown in Table 2: TC, TG and LDL in the dependent obvious reduction hyperlipidemia Carnis Coturnicis japonicae serum of this prescription dosage.
This prescription of table 2 is to the effect for reducing fat of hyperlipidemia Carnis Coturnicis japonicae
The solid serum glycerol three high density lipoprotein level low-density lipoproteins of the total gallbladder of dosage serum
Group
(g/kg) alcohol (mg/dl) fat (mmol/L white (mmol/L) white (mmol/L)
Matched group 6.33 ± 1.27 0.89 ± 0.22 7.64 ± 1.29 0.89 ± 0.22
Moulding group normal saline 9.97 ± 1.65## 2.52 ± 0.39## 8.25 ± 1.27 2.52 ± 0.39##
This 0.1 8.45 ± 1.40*, 2.11 ± 0.37* 7.77 ± 1.39 2.11 ± 0.37* that fills a prescription
This 0.2 7.71 ± 1.38**, 1.89 ± 0.25** 8.03 ± 1.21 1.89 ± 0.25** that fills a prescription
This 0.4 7.38 ± 1.19**, 1.61 ± 0.27** 8.61 ± 1.27 1.61 ± 0.27** that fills a prescription
Clofibrate 0.07 8.74 ± 1.44 2.06 ± 0.31** 8.30 ± 1.22 2.06 ± 0.31**
X ± SD, n=12, * p＜0.05, * * p＜0.01 and moulding group compare ##p＜0.01 and matched group compares
Test example 3: prescription of the present invention is to the protective effect of rat heart muscle infarction
60 of male rats are divided into matched group (normal saline) at random, this prescription 0.1g/kg, 0.2g/kg, 0.4g/kg group, verapamil 5mg/kg group.Each group is continuous 1 week of gastric infusion respectively, behind the 7th day administration 1h, and pentobarbital sodium anesthesia, the 3-4 intercostal is opened breast, cuts off pericardium, extrudes heart, pricks branch of coronary artery, closed-chest with the not damaged toe-in.S-T section when 1min, 15min after the ligation, 30min respectively organized in record respectively changes, and behind 6h, take out heart, remove left atrium, the bottom becomes the 0.1cm slab with myocardium truncation from the apex of the heart to the heart, put into the NBT dyeing liquor, 37 ℃ of dyeing 15min cut the ischemic necrosis tissue of not catching color then, weigh and calculate the percentage ratio that accounts for total myocardium weight.
The results are shown in Table 3: the myocardial infarction area that the dependent obvious reduction rat coronary ligation of this prescription dosage causes.And the S-T section that causes behind the rat coronary ligation has been raised significant protective effect.
This prescription of table 3 is to the effect of rat heart muscle infarction
The dosage myocardial infarction area
S-T section (mv) behind the group ischemia
(g/kg) (% percentage by weight)
1min 15min 30min
Matched group normal saline 29.9 ± 3.80 0.55 ± 0.12 0.57 ± 0.12 0.57 ± 0.08
This 0.1 26.8 ± 2.78* 0.52 that fills a prescription ± 0.10 0.5 3 ± 0.10 0.5 5 ± 0.09
This 0.2 24.8 ± 2.68** 0.53 that fills a prescription ± 0.08 0.50 ± 0.14 0.51 ± 0.07
This 0.4 23.2 ± 2.39** 0.53 that fills a prescription ± 0.10 0.48 ± 0.07*, 0.46 ± 0.09**
Verapamil 5mg 23.1 ± 2.72** 0.53 ± 0.07 0.45 ± 0.07*, 0.40 ± 0.09**
X ± SD, n=12, * p＜0.05, * * p＜0.01 and matched group are relatively
Test example 4: prescription of the present invention brings out the effect of myocardial ischemia to the rat pituitary pituitrin
60 of male Wister rats are divided into matched group (normal saline) at random, this prescription 0.1g/kg, 0.2g/kg, 0.4g/kg group, nifedipine 1mg/kg group, continuous one week of gastric infusion respectively.After irritating stomach 1h in the 7th day, pentobarbital sodium anesthesia, record II lead electrocardiogram, normal voltage 1mv=20mm, chart speed 50mm/s is after waiting to stablize, by tail vein injection pituitrin 1u/kg, annotated in the 5s, the electrocardiogram in record injection back 5s, 1min, 5min, 15min, 30min, the 1h changes, and mainly observes the displacement and the changes in heart rate of S-T section.
The results are shown in Table 4 and table 5: after control rats was given pituitrin, heart rate obviously slowed down, and the persistent period begins not return to former level yet to 1h from 5s; The tangible ST section of the first phase (1-30s) appearance is raised with the T wave height and is alarmmed, even forms monophasic curve; The second phase (behind the 30s) 1-7min tangible ST section occurs and moves down, and the T ripple does not have significant change.The ST section that this prescription causes the rat pituitary pituitrin changes tool and improves significantly, and the decreased heart rate that pituitrin is caused recovers normal, and its action intensity is similar to nifedipine.
This prescription of table 4 brings out the influence of rat ECG ST section displacement to pituitrin
Dosage group S-T section moves (mv)
(g/kg)
Prescription 0.4 0.14 ± 0.04 0.17 ± 0.09 0.11 ± 0.04 0.13 ± 0.07 0.16 ± 0.05 nifedipine 1mg 0.14 ± 0.05 0.22 ± 0.05**, 0.09 ± 0.04** 0.15 ± 0.05 0.12 ± 0.04, prescription 0.2 0.15 ± 0.04 0.1 3 ± 0.06 0.03 ± 0.04** 0.15 ± 0.05 0.18 ± 0.07,0.16 ± 0.08 prescription of 5s 1min 5min 15min control group physiological saline 0.14 ± 0.04 0.27 ± 0.09**, 0.02 ± 0.04** 0.01 ± 0.06**, 0.1 0.14 ± 0.03 0.27 ± 0.07**, 0.01 ± 0.05** 0.16 ± 0.05 0.17 ± 0.05 before the medicine
X ± SD compares before the n=12, * * p＜0.01 and medicine
The influence of the changes in heart rate that this prescription of table 5 causes pituitrin
5s 1min 5min 15min 30min 1h before the dosage group medicine
(g/kg) control group physiological saline 206 ± 25 144 ± 37**, 147 ± 29**, 137 ± 16**, 138 ± 13**, 173 ± 22**, 174 ± 25** 182 ± 39 212 ± 13 prescriptions of 189 ± 19 of 0.1 204 ± 24 154 ± 23**, 150 ± 23**, 138 ± 15**, 146 ± 24**, 173 ± 19** prescription, 0.2 197 ± 17 173 ± 18 148 ± 40**, 142 ± 29**, 145 ± 19**, 0.4 207 ± 15 210 ± 25 162 ± 34**, 141 ± 28**, 156 ± 36**, 187 ± 32 190 ± 30 nifedipine 1mg 202 ± 24 196 ± 27 149 ± 29**, 142 ± 30**, 149 ± 27**, 182 ± 23** 190 ± 24 that originally fill a prescription
X ± SD compares before the n=12, * * p＜0.01 and medicine
Clinical drug treatment coronary heart disease of the present invention, hyperlipidemia 330 examples.The result shows, this prescription is to cholesterol reducing, triglyceride, high density lipoprotein increasing, and improving blood supply of cardiac muscle has positive effect.
Relevant diagnostic criteria for coronary heart disease by the proposition of the academic annual meeting cardiovascular of first internal medicine in the whole nation, Guangzhou in 1980 professional organization, and coronary heart disease, angina pectoris name and the diagnostic criteria passed through with reference to The World Health Organization (WHO), select coronary heart disease stable angina pectoris 224 examples year March April to 1996 nineteen ninety-five, for patient's safety, unstable angina pectoriss such as syndrome, postinfarction angina pectoris are not as the object of selecting before variant angina pectoris, the infarction.The no obvious angina pectoriss of other 106 examples, but the blood fat height (TC＞230mg%, TG＞160mg%) is also as the lipid-lowering effect of this prescription of alternative primary part observation.Amount to 330 examples like this; wherein male 216 examples; woman's 114 examples; age 26-78 year, average 51.7 years old, wherein angina pectoris merged hyperlipidemia person's 168 examples; normal or approaching normal person's 56 examples of blood fat; hypertension patient's 44 examples that the merging degree is different merge type ii diabetes person 18 examples, 106 routine hyperlipidemia complicated hypertension patient 24 examples.
Take this prescription all lowering blood fat and dilating coronary artery medicines of stopping using of 1-2 before, the angina pectoris decubitus person can suitably add and uses cardiac diuretic, but do not add with medicines such as vasodilation sorbitrates, meals and living habit as usual, treatment target is 2 of taking medicine after meales for each person every day, every day the 4-6 grain, serveing on 15 days is a course of treatment, general hyperlipidemia person obeys the 1-2 course of treatment, and the angina pectoris person obeys 2 courses of treatment, and 48 examples due to illness feelings need interim buccal nitroglycerin with interim allevating angina pectoris.Other 116 routine coronary heart disease hyperlipemias are only obeyed propylene glycol alginate sodium sulfate 50mg, and every day three times, in contrast, the course of treatment and observed content are identical with this prescription.Accurate recording angina pectoris every day number of times, degree, outbreak inducement before the treatment, recording ecg, blood pressure, heart rate, cardiac rhythm, routine blood test, platelet, blood glucose, blood fat, hepatic and renal function, to ECG change is not obvious at ordinary times, but treadmill exercise is tested positive person and is write down its ST-T and change.
Efficacy assessment standard:
(1) it is normal that produce effects: ST-T recovers; TC descends＞=20%; TG descends＞=40%; HDL-C rising＞=0.209mmol/L
(2) effective: ST-T is than improving in the past; TC decline 10%-20%; TG decline 20%-39%; HDL-C rising＞=0.104-0.209mmol/L
(3) invalid: as not reach effective standard person
(4) worsen: ST-T changes not obvious or increases the weight of; TC rises＞=10%; TG rises 10%; HDL-C decline＞=0.104mmol/L
Clinical test results sees Table 6 and table 7:
These 186 18.8 50 30.1 68.8 propylene glycol alginate sodium sulfates 104 25 37.5 37.5 62.5 of filling a prescription of effective (%) invalid (%) of efficacy evaluation group example digital display effect (%) total effectively (%) that table 6 patient with angina pectoris is taken behind the medicine of the present invention are annotated: 224 routine patient with angina pectoris, electrocardiogram has ST-T changer 1 86 examples at ordinary times
Table 7 hyperlipidemia is taken variation observation index treatment preceding (mg%) treatment back (mg%) P value cholesterol 284.36 ± 25.68 247.62 ± 31.86＜0.01 triglycerides 204.13 ± 53.43 164.83 ± 41.26＜0.01 HDL4 5.86 ± 9.14 50.23 ± 7.66＜0.01 of medicine of the present invention front and back serum lipid concentrations
Annotate: hyperlipemia totally 274 examples in 330 examples, wherein simple hyperlipidemia 106 examples, coronary heart disease merges hyperlipidemia person's 168 examples
Visible this prescription has the effect of tangible cholesterol reducing, triglyceride and raising high density lipoprotein from table 6 and table 7, and is also more satisfactory to the Electrocardiographic improvement of angina pectoris.Poisonous side effect of medicine of the present invention in addition is slight, taking convenience, and removing indivedual cases has laxativeness, defecate thinningly not see that untoward reaction is obviously arranged in addition.
Claims (1)
1. prescription for the treatment of hyperlipidemia is characterized in that it comprises following prescription (by weight percentage):
Radix Et Rhizoma Rhei 30-50% Semen Cassiae 30-40% Radix Salviae Miltiorrhizae 10-20%
Pericarpium Citri Reticulatae 5-10% Radix Ginseng 2-5% Poria 2-5%
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03109063 CN1207036C (en) | 2003-04-03 | 2003-04-03 | Traditional Chinese medicine formule for treating hyperlipemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03109063 CN1207036C (en) | 2003-04-03 | 2003-04-03 | Traditional Chinese medicine formule for treating hyperlipemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1449783A true CN1449783A (en) | 2003-10-22 |
| CN1207036C CN1207036C (en) | 2005-06-22 |
Family
ID=28683927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03109063 Expired - Lifetime CN1207036C (en) | 2003-04-03 | 2003-04-03 | Traditional Chinese medicine formule for treating hyperlipemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1207036C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101376016B (en) * | 2008-10-06 | 2010-10-13 | 梁竹 | Method for preparing Chinese medicine for treating hyperlipemia |
| CN106176907A (en) * | 2016-08-31 | 2016-12-07 | 哈尔滨医科大学 | Raise for reducing the blood fat caused by high fat diet, Chinese medicine composition of fat and prevention and treatment hyperlipemia and application thereof |
-
2003
- 2003-04-03 CN CN 03109063 patent/CN1207036C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101376016B (en) * | 2008-10-06 | 2010-10-13 | 梁竹 | Method for preparing Chinese medicine for treating hyperlipemia |
| CN106176907A (en) * | 2016-08-31 | 2016-12-07 | 哈尔滨医科大学 | Raise for reducing the blood fat caused by high fat diet, Chinese medicine composition of fat and prevention and treatment hyperlipemia and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1207036C (en) | 2005-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN104288345A (en) | A traditional Chinese medicine composition assisting blood lipid reduction and a preparing method thereof | |
| CN1155375C (en) | Linolic acid and linolenic acid capsule and its making process | |
| CN1771944A (en) | Application of high-solubility berberine in preparing medicine | |
| CN1207036C (en) | Traditional Chinese medicine formule for treating hyperlipemia | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN102188699A (en) | Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN101829271A (en) | Chinese medicinal compound with function of treating diabetes and preparation method and application thereof | |
| CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
| CN101361797A (en) | Traditional Chinese medicine pressure-reduction insoles | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN1714836A (en) | Use of medicine in preparing medicine for treating anti-aspirin | |
| CN1248684C (en) | Chinese medicine powder for curing cardiovascular disease and preparing method thereof | |
| CN103341069B (en) | Tibetan medicament for treating angina pectoris and preparation method thereof | |
| CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
| CN100563704C (en) | The saturating subsides of distension umbilicus and preparation method thereof that disappear of treatment liver cirrhosis tympanites | |
| CN1135996C (en) | Chinese medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1682972A (en) | Chinese medicine composition for treating cardiovascular disease and its preparing method | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| CN1872317A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1663600A (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| CN1555839A (en) | Medicne for treating primary hypertension and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151224 Address after: 150086 Nangang City, Heilongjiang Province Health Road, No. 157, Patentee after: Harbin Medical University Address before: 150086 No. 157 health Road, Heilongjiang, Harbin Patentee before: Yang Baofeng Patentee before: Fang Zhiwei Patentee before: Chen Qingwen |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160111 Address after: 1, 150080 floor, No. 196, Xuefu Road, Nangang District, Heilongjiang, Harbin, 5 Patentee after: Harbin Medical University Asset Management Co.,Ltd. Address before: 150086 Nangang City, Heilongjiang Province Health Road, No. 157, Patentee before: Harbin Medical University |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190123 Address after: 150081 157 health Road, Nangang District, Harbin, Heilongjiang Patentee after: HARBIN MEDICAL University Address before: 150080 5 stories, No. 196 Xuefu Road, Nangang District, Harbin City, Heilongjiang Province Patentee before: Harbin Medical University Asset Management Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050622 |
|
| CX01 | Expiry of patent term |